Effect of methylprednisolone on leves of interleukin-23 and interleukin-17 in serum and cerebrospinal fluid in patients with relapsing-remitting multiple sclerosis
10.3760/cma.j.issn.1671-8925.2014.03.018
- VernacularTitle:甲基强的松龙对复发缓解型多发性硬化血清及脑脊液白介素-23、白介素-17水平的影响
- Author:
Junli LIANG
1
;
Lijun ZHAO
;
Haidong LYU
;
Yuming XU
Author Information
1. 郑州大学第一附属医院神经内三科
- Keywords:
Relapsing-remitting multiple sclerosis;
Methylprednisolone;
Interleukin-23;
Interleukin-17
- From:
Chinese Journal of Neuromedicine
2014;13(3):301-303
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the role of interleukin-23 (IL-23) and IL-17 in the pathogenesis of relapsing-remitting multiple sclerosis (RRMS),and determine the effect of methylprednisolone on IL-23 and IL-17 levels.Methods Twenty-nine patients with RRMS (RRMS group) and patients with non-inflammatory neurological diseases (controls),admitted to our hospitals from June 2010 to December 2012 group,were chosen in our study; ELISA was employed to detect the serum and cerebrospinal fluid levels of IL-23 and IL-17 in the two groups before and after methylprednisolone treatment.Results Before treatment,IL-23 and IL-17 levels in serum and cerebrospinal fluid of RRMS group (IL-23:[689.66±111.61] pg/mL and [768.82±70.63] pg/mL; IL-17:[88.15±13.16] pg/mL and [91.51±12.45] pg/mL) were significantly higher than those in the control group (IL-17:[90.94±10.70] pg/mL and [85.71±7.21] pg/mL; IL-23:[17.14±1.55] pg/mL and [17.87±1.61] pg/mL],P＜0.05),and the IL-23 level in cerebrospinal fluid was significantly higher than that in serum (P＜0.05); IL-23 and IL-17 levels in RRMS group after treatment (IL-23:[399.91±61.73] pg/mL and [319.34±91.29] pg/mL; IL-17:[48.01±9.62] pg/mL and [49.08±13.72] pg/mL]) significantly decreased as compared with those before treatment (P＜0.05),but they were still statistically higher than those in the control group (P＜0.05).IL-17 and IL-23 levels had positive correlation in the serum and cerebrospinal fluid of RRMS group (r=0.369,P=0.049; r=0.497,P=0.006).Conclusion IL-23 and IL-17 levels are associated with the pathogenesis of multiple sclerosis; methylprednisolone treatment can decrease the levels of IL-23 and IL-17 in multiple sclerosis.
